Printer Friendly

Was alendronate really ineffective?

"CONSIDER DENOSUMAB FOR POST-MENOPAUSAL OSTEPOROSIS"

ROBERT L. BARBIERI, MD

(EDITORIAL; JANUARY 2011)

In his editorial, Dr. Barbieri presented the case of a woman who initiated denosumab after alendronate failed to increase her bone density. He later characterized that alendronate therapy as "unsuccessful." I wonder if Dr. Barbieri could clarify what he means by that assessment. Given that the woman's T-score at her hip remained stable despite concomitant use of an aromatase inhibitor, I would not necessarily conclude that it was unsuccessful.

Ronald Orleans, MD

Bethesda, Md

Dr. Barbieri responds:

Assessing, the effect of alendronate is not always simple I appreciate Dr. Orleans's comment and the time he took from his busy practice to raise a clinically important issue. I agree with him: Determining whether alendronate therapy has been successful in the treatment of osteoporosis is not straightforward. In most patients, if bone density increases or remains stable, alendronate therapy is considered successful. If bone density decreases, as it did in this patient, the question arises: How much of a decrease in bone density is clinically or statistically significant? One approximation that can be made is if bone density, as measured in grams per square centimeter, decreases by 4.16%, there is a 95% likelihood that it represents a real decrease--one that would be reproduced if the test were performed over and over again. In addition to a decrease in bone mineral density, this patient also had a low-impact fracture, strongly suggesting that the alendronate was not highly effective in her case.

[ILLUSTRATION OMITTED]

Reference

(1.) Bonnick SL, Johnston CC, Kleerekoper M, et al. Importance of precision in bone-density measurements. J Clin Densitom. 2001;4(2):105-110.

COPYRIGHT 2011 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Comment & Controversy
Author:Orleans, Ronald
Publication:OBG Management
Geographic Code:1USA
Date:Mar 1, 2011
Words:276
Previous Article:Levonorgestrel or ulipristal: is one a better emergency contraceptive than the other? Comparison of these two FDA-approved agents should take more...
Next Article:Another maneuver to stanch postpartum hemorrhage.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |